A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

J. Kellogg Parsons, Peter A. Pinto, Christian P. Pavlovich, Edward Uchio, Hyung L. Kim, Mikel N. Nguyen, James L. Gulley, Christina Jamieson, Paul Hsu, Margarita Wojtowicz, Howard Parnes, Jeffrey Schlom, William L. Dahut, Ravi A. Madan, Renee N. Donahue, H. H.Sherry Chow

Research output: Contribution to journalComment/debatepeer-review

8 Scopus citations

Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

Original languageEnglish (US)
Pages (from-to)636-638
Number of pages3
JournalEuropean Urology Focus
Volume4
Issue number5
DOIs
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study'. Together they form a unique fingerprint.

Cite this